McGlinchey Ryan P, Lee Jennifer C
Laboratory of Molecular Biophysics, Biochemistry and Biophysics Center, National Heart, Lung, and Blood Institute, Bethesda, MD 20892.
Laboratory of Molecular Biophysics, Biochemistry and Biophysics Center, National Heart, Lung, and Blood Institute, Bethesda, MD 20892
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9322-7. doi: 10.1073/pnas.1500937112. Epub 2015 Jul 13.
A cellular feature of Parkinson's disease is cytosolic accumulation and amyloid formation of α-synuclein (α-syn), implicating a misregulation or impairment of protein degradation pathways involving the proteasome and lysosome. Within lysosomes, cathepsin D (CtsD), an aspartyl protease, is suggested to be the main protease for α-syn clearance; however, the protease alone only generates amyloidogenic C terminal-truncated species (e.g., 1-94, 5-94), implying that other proteases and/or environmental factors are needed to facilitate degradation and to avoid α-syn aggregation in vivo. Using liquid chromatography-mass spectrometry, to our knowledge, we report the first peptide cleavage map of the lysosomal degradation process of α-syn. Studies of purified mouse brain and liver lysosomal extracts and individual human cathepsins demonstrate a direct involvement of cysteine cathepsin B (CtsB) and L (CtsL). Both CtsB and CtsL cleave α-syn within its amyloid region and circumvent fibril formation. For CtsD, only in the presence of anionic phospholipids can this protease cleave throughout the α-syn sequence, suggesting that phospholipids are crucial for its activity. Taken together, an interplay exists between α-syn conformation and cathepsin activity with CtsL as the most efficient under the conditions examined. Notably, we discovered that CtsL efficiently degrades α-syn amyloid fibrils, which by definition are resistant to broad spectrum proteases. This work implicates CtsB and CtsL as essential in α-syn lysosomal degradation, establishing groundwork to explore mechanisms to enhance their cellular activity and levels as a potential strategy for clearance of α-syn.
帕金森病的一个细胞特征是α-突触核蛋白(α-syn)在细胞质中积累并形成淀粉样蛋白,这意味着涉及蛋白酶体和溶酶体的蛋白质降解途径存在失调或受损。在溶酶体内,天冬氨酸蛋白酶组织蛋白酶D(CtsD)被认为是清除α-syn的主要蛋白酶;然而,仅该蛋白酶只能产生具有淀粉样蛋白生成性的C末端截短产物(例如,1-94、5-94),这意味着需要其他蛋白酶和/或环境因素来促进降解并避免α-syn在体内聚集。据我们所知,通过液相色谱-质谱联用技术,我们报告了α-syn溶酶体降解过程的首个肽段切割图谱。对纯化的小鼠脑和肝溶酶体提取物以及个体人类组织蛋白酶的研究表明,半胱氨酸组织蛋白酶B(CtsB)和L(CtsL)直接参与其中。CtsB和CtsL均在α-syn的淀粉样蛋白区域内切割α-syn,并避免原纤维形成。对于CtsD,只有在存在阴离子磷脂的情况下,该蛋白酶才能在整个α-syn序列上进行切割,这表明磷脂对其活性至关重要。综上所述,在我们所研究的条件下,α-syn构象与组织蛋白酶活性之间存在相互作用,其中CtsL最为高效。值得注意的是,我们发现CtsL能有效降解α-syn淀粉样原纤维,而根据定义,这种原纤维对广谱蛋白酶具有抗性。这项工作表明CtsB和CtsL在α-syn溶酶体降解中至关重要,为探索增强它们的细胞活性和水平的机制奠定了基础,以此作为清除α-syn的潜在策略。